# Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment

> **NCT01235949** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 850 (actual)

## Conditions studied

- Infections, Streptococcal

## Interventions

- **BIOLOGICAL:** GSK1024850A (SynflorixTM)
- **BIOLOGICAL:** Infanrix hexa
- **BIOLOGICAL:** Infanrix-IPV/Hib
- **DRUG:** Ibuprofen
- **DRUG:** Paracetamol

## Key facts

- **NCT ID:** NCT01235949
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11-12
- **Primary completion:** 2012-03-28
- **Final completion:** 2012-12-08
- **Target enrollment:** 850 (ACTUAL)
- **Last updated:** 2019-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01235949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01235949, "Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01235949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*